BioAge Labs completes IND-enabling studies for BGE-102

BioAge Labs (BIOA) announced completion of IND-enabling studies for BGE-102 and updated clinical development milestones for the compound. BGE-102 is a structurally novel, orally available small-molecule NLRP3 inhibitor with high potency and brain penetration. BioAge is initially developing BGE-102 for the treatment of obesity. In preclinical models of obesity, BGE-102 monotherapy produced dose-dependent weight loss similar in magnitude to semaglutide, with optimal doses achieving approximately 15% weight reduction. The weight loss, driven by reduced food intake, was sustained over 28 days of treatment. BGE-102 treatments also yielded improvements in insulin sensitivity, similar in magnitude to those seen with semaglutide. “By inhibiting the NLRP3 inflammasome, BGE-102 targets a core pathway that links metabolism, inflammation, and aging,” said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Its potential potency, brain penetration, and pharmacokinetics which suggest the possibility for once-daily dosing position BGE-102 as a convenient oral therapy for obesity-either alone or alongside GLP-1 receptor agonists-and may unlock additional opportunities in diseases driven by NLRP3-mediated inflammation.”